TY - JOUR
T1 - Butyrylcholinesterase attenuates amyloid fibril formation in vitro
AU - Diamant, Sophia
AU - Podoly, Erez
AU - Friedler, Assaf
AU - Ligumsky, Hagai
AU - Livnah, Oded
AU - Soreq, Hermona
PY - 2006/6/6
Y1 - 2006/6/6
N2 - In Alzheimer's disease, both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) colocalize with brain fibrils of amyloid-β (Aβ) peptides, and synaptic AChE-S facilitates fibril formation by association with insoluble Aβ fibrils. Here, we report that human BChE and BSP41, a synthetic peptide derived from the BChE C terminus, inversely associate with the soluble Aβ conformers and delay the onset and decrease the rate of Aβ fibril formation in vitro, at a 1:100 BChE/Aβ molar ratio and in a dose-dependent manner. The corresponding AChE synthetic peptide (ASP)40 peptide, derived from the homologous C terminus of synaptic human (h)AChE-S, failed to significantly affect Aβ fibril formation, attributing the role of enhancing this process to an AChE domain other than the C terminus. Circular dichroism and molecular modeling confirmed that both ASP40 and BChE synthetic peptide (BSP)41 are amphipathic α-helices. However, ASP40 shows symmetric amphipathicity, whereas BSP41 presented an aromatic tryptophan residue in the polar side of the C terminus. That this aromatic residue is causally involved in the attenuating effect of BChE was further supported by mutagenesis experiments in which (W8R) BSP41 showed suppressed capacity to attenuate fibril formation. In Alzheimer's disease, BChE may have thus acquired an inverse role to that of AChE by adopting imperfect amphipathic characteristics of its C terminus.
AB - In Alzheimer's disease, both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) colocalize with brain fibrils of amyloid-β (Aβ) peptides, and synaptic AChE-S facilitates fibril formation by association with insoluble Aβ fibrils. Here, we report that human BChE and BSP41, a synthetic peptide derived from the BChE C terminus, inversely associate with the soluble Aβ conformers and delay the onset and decrease the rate of Aβ fibril formation in vitro, at a 1:100 BChE/Aβ molar ratio and in a dose-dependent manner. The corresponding AChE synthetic peptide (ASP)40 peptide, derived from the homologous C terminus of synaptic human (h)AChE-S, failed to significantly affect Aβ fibril formation, attributing the role of enhancing this process to an AChE domain other than the C terminus. Circular dichroism and molecular modeling confirmed that both ASP40 and BChE synthetic peptide (BSP)41 are amphipathic α-helices. However, ASP40 shows symmetric amphipathicity, whereas BSP41 presented an aromatic tryptophan residue in the polar side of the C terminus. That this aromatic residue is causally involved in the attenuating effect of BChE was further supported by mutagenesis experiments in which (W8R) BSP41 showed suppressed capacity to attenuate fibril formation. In Alzheimer's disease, BChE may have thus acquired an inverse role to that of AChE by adopting imperfect amphipathic characteristics of its C terminus.
KW - Alzheimer's disease
KW - Aromatic
KW - C-terminal peptide
KW - Cholinesterase
KW - Site-directed mutagenesis
UR - http://www.scopus.com/inward/record.url?scp=33745015720&partnerID=8YFLogxK
U2 - 10.1073/pnas.0602922103
DO - 10.1073/pnas.0602922103
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 16731619
AN - SCOPUS:33745015720
SN - 0027-8424
VL - 103
SP - 8628
EP - 8633
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 23
ER -